In the February 2011 edition of Current Medical Research and Opinion a new report (1), Modelled cost-effectiveness of high cut-off haemodialysis (HCO-HD) compared to standard haemodialysis in the management of myeloma kidney, applied an economic model to calculate the lifetime treatment costs per patient for myeloma kidney patients treated with HCO-HD versus standard HD. The results showed that, for the patient population used in the model, HCO-HD was less costly than standard HD, primarily due to an increase in the proportion of patients recovering renal function.
The study used a Lifetime Excel-based decision tree model – following patients from treatment of the initial presentation of myeloma kidney (requiring dialysis) to death. The model was populated with published clinical data, United Kingdom costs and expert opinion, using a National Health Service perspective.
The model projected lifetime costs of £31,345 per patient for patients treated with standard hemodialysis only and £24,845 for patients treated with HCO-HD.
"This is an important step in understanding the potential benefits of the Theralite membrane and HCO-HD and is a valuable guide for those looking to adopt or reimburse the therapy" Andrew Gill - Marketing Manager Ventures.
(1) - Daniel Grima, Colin Hutchinson. Current Medical Research & Opinion Vol. 27, No.2, 2011, 383 – 391. Mr. Grima is employed by Cornerstone Research Group, Inc. which received funding from Gambro AB to develop an economic model and conduct the cost-effectiveness analysis using that model and prepare the manuscript. Dr. Hutchinson at Queen Elizabeth Hospital, University Hospital, Birmingham, UK has previously received speaker’s fees from Gambro AB.
* Theralite has Humanitarian Use Device designation status in the U.S. for use to remove serum free light chains (FLC) which can lead to cast acute renal failure in patients with multiple myeloma. The effectiveness of this device for this use has not been demonstrated.